High tacrolimus blood concentrations early after lung transplantation and the risk of kidney injury

M. A. Sikma, C. C. Hunault, E. A. van de Graaf, M. C. Verhaar, J. Kesecioglu, D. W. de Lange, J. Meulenbelt
  • European Journal of Clinical Pharmacology, January 2017, Springer Science + Business Media
  • DOI: 10.1007/s00228-017-2204-8

What is it about?

What is known about this subject? • Lung-transplant recipients often develop acute kidney injury evolving into chronic kidney disease increasing both morbidity and mortality • To date, the pathophysiology of acute kidney injury after lung transplantation has not been fully elucidated • The immunosuppressant tacrolimus, which is nephrotoxic, is difficult to dose in the unstable clinical setting What this study adds: • Supra-therapeutic whole-blood tacrolimus trough concentrations are related to the emergence of acute kidney injury in the first days after lung transplantation • Supra-therapeutic whole-blood tacrolimus trough concentrations often occur early after lung transplantation • AKI after lung transplantation shows low recovery rates and often evolves to severe chronic kidney

Perspectives

Ms Maaike A. Sikma
UMC Utrecht

This study underlines the significance of unraveling tacrolimus pharmacokinetics early after transplantation to decrease AKI in this vulnerable group of patients.

Read Publication

http://dx.doi.org/10.1007/s00228-017-2204-8

The following have contributed to this page: Ms Maaike A. Sikma

In partnership with: